May 20, 2019

PPMD’s Certified Duchenne Care Center Program – 2018 Impact & Progress

For 25 years, care has been at the heart of everything PPMD does. We strive to ensure that people living with Duchenne are living longer, stronger lives, by helping you access expert healthcare providers, a…

Learn More

May 14, 2019

Solid Biosciences Provides Update on IGNITE DMD Status and New Clinical Sites

Solid Biosciences shared an update on the progress of their IGNITE DMD Phase I/II clinical trial for investigational microdystrophin gene transfer, SGT-001. The update includes news about initiating dosing for their higher dose cohort of…

Learn More

May 13, 2019

WATCH: Santhera Update to the Duchenne Community – Webinar Recording

On May 8, 2019, Santhera joined Parent Project Muscular Dystrophy for a webinar to provide the community with an update about respiratory health in Duchenne muscular dystrophy and the ongoing SIDEROS clinical trial. If you…

Learn More

April 30, 2019

WATCH: Capricor’s Clinical Program – Webinar Recording

On Wednesday, April 24, 2019, Capricor joined Parent Project Muscular Dystrophy for a webinar to update the community on Capricor’s HOPE2 clinical program. If you missed the live event, the recording can be found below….

Learn More

April 16, 2019

Wave Life Sciences Announces Suvodirsen Phase 1 Safety and Tolerability Data and Phase 2/3 Clinical Trial Design

Wave Life Sciences shared safety and tolerability data from their Phase 1 clinical trial evaluating investigational suvodirsen (WVE-210201) in patients with Duchenne. The results from this trial support progressing to a Phase 2/3 clinical trial,…

Learn More

April 15, 2019

FibroGen Receives U.S. FDA Orphan Drug Designation for Pamrevlumab for the Treatment of Duchenne

FibroGen announced that FDA has granted Orphan Drug Designation for the company’s anti-CTGF antibody, pamrevlumab, for the treatment of people with Duchenne. According to their press release, all 21 non-ambulatory Duchenne patients in their ongoing…

Learn More

April 8, 2019

Audentes Therapeutics Announces Expansion of AAV Technology Platform and Pipeline for Duchenne

Audentes Therapeutics announced that it is expanding its scientific platform and beginning development of new AAV-based genetic medicines for Duchenne. Audentes is a leading AAV-based genetic medicines company based in San Francisco. The company is…

Learn More

April 5, 2019

Catabasis Shares March 2019 Newsletters

Catabasis shared the latest edition of their community newsletter (also available in Spanish), including an update on their currently recruiting Phase 3 PolarisDMD trial for edasalonexent in Duchenne. Download the Catabasis newsletters: English Spanish

Learn More

April 3, 2019

WATCH: Italfarmaco Provides Givinostat Update – Webinar Recording

On Wednesday, March 27, 2019, Italfarmaco joined Parent Project Muscular Dystrophy for a webinar to update the community about Italfarmaco’s development of Givinostat and currently enrolling Phase 3 confirmatory study in Duchenne muscular dystrophy. If…

Learn More

March 28, 2019

Sarepta Announces Positive Expression Results from the Casimersen (SRP-4045) Arm of ESSENCE Study

Sarepta Therapeutics announced positive results from its interim analysis of muscle biopsies at week 48, comparing casimersen treatment to placebo in the ESSENCE study, also known as study 4045-301. ESSENCE is a global, randomized double-blind,…

Learn More